国际中医临床实践指南 焦虑症

2021-04-01 世界中医药学会联合会 世界中医药学会联合会

本指南的起草程序遵守了世界中医药学会联合会发布的《世界中医药学会联合会国际组织标准管理办法》和SCM 0001-2009《标准制定和发布工作规范》。

中文标题:

国际中医临床实践指南 焦虑症

发布日期:

2021-04-01

简要介绍:

国际中医临床实践指南焦虑症(以下简称“本指南”)是在中华中医药学会2008年发布的《中医内科常见疾病诊疗指南·焦虑症》(标准号:ZYYXH/T 132-2008)基础上,结合近年来的海内外临床研究证据,进行证据分级和意见推荐,经过专家讨论,而形成的焦虑症国际中医临床实践指南。本指南的起草程序遵守了世界中医药学会联合会发布的《世界中医药学会联合会国际组织标准管理办法》和SCM 0001-2009《标准制定和发布工作规范》。本指南由世界中医药学会联合会发布,版权归世界中医药学会联合会所有。

下载附件:

(因为版权问题,不支持下载)

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1210742, encodeId=31b01210e42b3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c212631393, createdName=283488816, createdTime=Wed Apr 13 05:59:41 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207078, encodeId=054c120e07895, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:35:43 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198787, encodeId=774b1198e875b, content=有价值, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048e6167235, createdName=ms1000001338777518, createdTime=Wed Mar 02 17:53:29 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187752, encodeId=5b6f118e752bf, content=好处多多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07632284054, createdName=121d0297m60暂无昵称, createdTime=Mon Jan 24 17:55:30 CST 2022, time=2022-01-24, status=1, ipAttribution=)]
    2022-04-13 283488816

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1210742, encodeId=31b01210e42b3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c212631393, createdName=283488816, createdTime=Wed Apr 13 05:59:41 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207078, encodeId=054c120e07895, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:35:43 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198787, encodeId=774b1198e875b, content=有价值, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048e6167235, createdName=ms1000001338777518, createdTime=Wed Mar 02 17:53:29 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187752, encodeId=5b6f118e752bf, content=好处多多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07632284054, createdName=121d0297m60暂无昵称, createdTime=Mon Jan 24 17:55:30 CST 2022, time=2022-01-24, status=1, ipAttribution=)]
    2022-03-30 56446_2968

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1210742, encodeId=31b01210e42b3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c212631393, createdName=283488816, createdTime=Wed Apr 13 05:59:41 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207078, encodeId=054c120e07895, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:35:43 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198787, encodeId=774b1198e875b, content=有价值, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048e6167235, createdName=ms1000001338777518, createdTime=Wed Mar 02 17:53:29 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187752, encodeId=5b6f118e752bf, content=好处多多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07632284054, createdName=121d0297m60暂无昵称, createdTime=Mon Jan 24 17:55:30 CST 2022, time=2022-01-24, status=1, ipAttribution=)]
    2022-03-02 ms1000001338777518

    有价值

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1210742, encodeId=31b01210e42b3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c212631393, createdName=283488816, createdTime=Wed Apr 13 05:59:41 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207078, encodeId=054c120e07895, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:35:43 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198787, encodeId=774b1198e875b, content=有价值, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048e6167235, createdName=ms1000001338777518, createdTime=Wed Mar 02 17:53:29 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187752, encodeId=5b6f118e752bf, content=好处多多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07632284054, createdName=121d0297m60暂无昵称, createdTime=Mon Jan 24 17:55:30 CST 2022, time=2022-01-24, status=1, ipAttribution=)]
    2022-01-24 121d0297m60暂无昵称

    好处多多

    0

拓展阅读

2016 WFSBP共识声明:焦虑症、强迫症和创伤后应激障碍的生物学标记

世界生物精神病学会联合会(WFSBP,World Federation of Societies of Biological Psychiatry) · 2016-07-12

2020 AACAP临床实践指南:儿童青少年焦虑症的评估和治疗

美国儿童和青少年精神病学会(AACAP,American Academy of Child and Adolescent Psychiatry) · 2020-05-18

2023 专家共识:不明焦虑症的管理

日本杏林大学医学院神经系(Department of Neuropsychiatry, Kyorin University Faculty of Medicine) · 2023-02-21

2023 NICE 卫生技术评价:成人焦虑症的数字化疗法的早期价值评估【HTE9】

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-05-16

2023 NICE 卫生技术评价:成人焦虑症的数字化疗法的早期价值评估【HTE8】

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-05-16